VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 61 filers reported holding VAXCYTE INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,511,017 | +82.7% | 637,721 | +78.9% | 0.00% | +100.0% |
| Q2 2023 | $17,799,066 | +62.1% | 356,409 | +21.7% | 0.00% | +100.0% |
| Q1 2023 | $10,977,000 | +90417.0% | 292,896 | +15.8% | 0.00% | -50.0% |
| Q4 2022 | $12,127 | -99.7% | 252,932 | +40.4% | 0.00% | +100.0% |
| Q3 2022 | $4,322,000 | +349.7% | 180,127 | +307.8% | 0.00% | – |
| Q2 2022 | $961,000 | +48.5% | 44,172 | +64.9% | 0.00% | – |
| Q1 2022 | $647,000 | +33.1% | 26,792 | +31.3% | 0.00% | – |
| Q4 2021 | $486,000 | -26.5% | 20,402 | -21.7% | 0.00% | – |
| Q3 2021 | $661,000 | +34.1% | 26,057 | +19.1% | 0.00% | – |
| Q2 2021 | $493,000 | -61.6% | 21,881 | -66.3% | 0.00% | – |
| Q1 2021 | $1,283,000 | +28.8% | 64,945 | +73.2% | 0.00% | – |
| Q4 2020 | $996,000 | +184.6% | 37,491 | +452.3% | 0.00% | – |
| Q3 2020 | $350,000 | – | 6,788 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |